The structural proteins of equine herpesvirus 2 (EHV-2) and EHV-5, recently shown to be gammaherpesviruses, were identified and compared. Labelled proteins and glycoproteins were separated by SDS-PAGE and although EHV-2 and EHV-5 had similar protein profiles, bands in some positions were virus-specific. Six glycoproteins, with distinct profiles, were identified for both EHV-2 and EHV-5. Rabbit antisera to EHV-2 and EHV-5 and horse antiserum to EHV-2 were used in radioimmunoprecipitations, Western blot analysis and ELISA to investigate the immunogenicity and cross-reactivity of virus proteins. These analyses revealed that while EHV-2 and EHV-5 proteins share many common epitopes, they also possess type-specific epitopes. A 0.71 kb region of the EHV-2 glycoprotein B (gB) gene was expressed as a fusion protein in Escherichia coli. Antiserum raised in a rabbit to the EHV-2 fusion protein was used to identify a 64K EHV-2 protein as EHV-2 gB. Antiserum to EHV-2 gB was used to identify a 66K EHV-5 protein as EHV-5 gB. These proteins, which may represent subunits of gB rather than the entire molecule, appear the most immunodominant of the structural virion proteins as identified by Western blot.
Introduction
Equine herpesvirus 2 (EHV-2) is a slowly growing, highly cell-associated virus that commonly infects horses. EHV-2 was originally included in the Betaherpesvirinae subfamily on the basis of its biological properties (Roizman et al., 1992) . It has been shown, however, that the virus shares greater amino acid sequence similarity with the gammaherpesviruses Epstein-Barr virus (EBV) and herpesvirus saimiri (HVS) than with any other herpesviruses, and should therefore be reclassified in the Gammaherpesvirinae subfamily (Telford et al., 1993) .
EHV-2 has been isolated from the leukocytes of 89 % of apparently normal horses (Kemeny & Pearson, 1970; Roeder & Scott, 1975) and also from the upper respiratory tract and conjunctiva, vagina, mammary gland, bone marrow, spleen and kidney (Plummer & Waterson, 1963; Kono & Kobayashi, 1964; Karpas, 1966; Studdert, 1971 ; Harden et al., 1974) . The precise role of EHV-2 in causing disease of the horse is uncertain. EHV-2 has been implicated in immunosuppression in foals, upper respiratory tract disease, conjunctivitis, general malaise and poor performance Studdert, 1971 ; Blakeslee et al., 1975; Palfi et al., 1978; Belak et al., 1980; Sugiura et al., 1983; Jolly et al., 1986) . It has also been suggested that EHV-2 may play a role in trans-activation and reactivation of latent EHV-1 (equine abortion virus) and EHV-4 (equine rhinopneumonitis virus; Welch et al., 1992) .
Considerable antigenic and biological heterogeneity among EHV-2 isolates has been reported. Different isolates exhibit variability in the rate of growth in cell culture and in plaque size (Plummer et al., 1969; Studdert et al., 1970; Plummer et al., 1973; Harden et al., 1974; Browning & Studdert, 1987) . Considerable antigenic heterogeneity between different EHV-2 isolates was demonstrated in cross-neutralization assays (Plummer et al., 1973) , in which it was found that the antibody titre of an antiserum against heterologous strains was, in most instances, markedly less than against the homologous strain.
The existence of a second type of slowly growing equine herpesvirus which was distinct from, and yet related to, EHV-2 was proposed by Browning & Studdert (1987) . In their study, examination of the genomic DNA profiles of 51 viruses assumed to be EHV-2 revealed that four viruses shared few, if any, comigrating fragments with the other 47 viruses, although their restriction patterns were virtually identical to each other. The four isolates were also found to grow more slowly and to have a smaller genome than typical EHV-2 isolates. The four viruses were provisionally designated EHV-5 (Browning & Studdert, 1987) . Further studies on the EHV-5 genome revealed that EHV-5 and EHV-2 DNA cross-hybridize to 0001-2233 © 1994 SGM only a limited degree and that the EHV-5 genome does not incorporate large internal or terminal repeat sequences, unlike the EHV-2 genome, which contains long (18 kb), direct, terminal repeats and an unrelated second pair of short, internal, indirect repeats (Browning & Studdert, 1989a; Agius et al., 1992) . The four known isolates of EHV-5 were obtained from three epidemiologically unrelated groups of horses. EHV-5 has not been identified elsewhere. To our knowledge, the horse is the only species known to be host for two distinct gammaherpesvirus types.
The genomes of EHV-2 and EHV-5 have been studied in some detail. Both genomes have been mapped for four restriction endonucleases (Browning & Studdert, 1989 a; Agius et al., 1992), and the DNA sequences of 39 kb of the EHV-2 genome and 42 kb of the EHV-5 genome have been determined (Telford et al., 1993) . The relationship between EHV-2 and EHV-5 and members of the Gammaherpesvirinae was established on the basis of amino acid sequence similarity (Telford et al., 1993) . Preliminary studies of the virion proteins of EHV-2 were reported by Caughman et al. (1984) , but the proteins of EHV-5 have not been described.
In this study, we describe the identification and comparison of the structural proteins and glycoproteins of EHV-2 and EHV-5. The immunogenicity and crossreactivity of EHV-2 and EHV-5 antigens were investigated using rabbit antisera to EHV-2 and EHV-5, and horse antiserum to EHV-2. Part of EHV-2 glycoprotein B (gB) was expressed in Escherichia coll. Antiserum raised in a rabbit to the EHV-2 gB fusion protein was used to identify a subunit of EHV-2 gB, and subsequently, a subunit of EHV-5 gB, which were the most immunodominant of the structural proteins identified.
Methods
Cells and viruses. EHV-5 strain 2-141 (EHV-5.2-141), EHV-2.86/67 , EHV-2.2-16, EHV-2.1-141 , EHV-2. F5N and EHV-2. F 1E (Studdert, 1971) were propagated in equine fetal kidney (EFK) monolayer cell cultures. Infected cells were maintained in MEM (Gibco BRL) containing Earle's salts, Lglutamine and non-essential amino acids, and supplemented with 1% fetal bovine serum, 8mg/ml gentamicin, 0.013M-NaHCO 3 and 0-015 M-HEPES (Sigma) at pH 7.5.
Infection, radiolabelling and virus purification. These were performed as described previously (Crabb & Studdert, 1990) , except that EHV-2.86/67, EHV-2.F5N and EHV-2. F1E were labelled at 16 h post-infection (p.i.) and purified from cell culture supernatants at approximately 90 h p.i. ; EHV-2.2-16 and EHV-2.1-141 were labelled at 24 h p.i. and purified at approximately 160 h p.i.; EHV-5.2-141 was labelled at 32 h p.i. and purified at approximately 330 h p.i.
Antisera. Antiserum to EHV-2.86/67 was raised by Gleeson & Studdert (1977) following in utero infection of an equine fetus. After birth, the infected foal was deprived of colostrum and artificially reared in an environment free of equine pathogens. The serum neutralizing antibody titre reached a peak 28 days after the birth of the foal, and this serum was used in the present study.
Other antisera were raised in young adult New Zealand White rabbits. Antisera to EHV-2.86/67 and EHV-5.2-141 purified virus were obtained following two intramuscular (i.m.) injections of virus in Freund's complete adjuvant and three in Freund's incomplete adjuvant, at 7 day intervals, followed 10 days later by an intravenous inocuIation. To prepare rabbit antisera to EHV-2 and EHV-5 gB fusion proteins, rabbits received an i.m. injection of 100 lag of protein in Freund's complete adjuvant, followed by two i.m. injections of 100 lag of protein in Freund's incomplete adjuvant at 10 day intervals. Rabbits were bled 5 to 9 days after the final inoculation. (RIP) and ELISA. SDS-PAGE and RIP were performed as described previously (Crabb & Studdert, 1990) . ELISA was performed as described by Crabb et al. (1991) using EHV-2 and EHV-5 purified virus, diluted to 10 mg/ml, to coat wells.
SDS-PAGE, radioimmunoprecipitation
Western blots. Proteins were separated by electrophoresis through 10% polyacrylamide gels before being transferred to Immobilon PVDF transfer membranes (Millipore) at 100 V for 1 h. The transfer buffer, in which the membrane and the gel were equilibrated prior to transfer, contained 20 % methanol, 50 mM-Tris-HC1, 380 mM-glycine and 0.1% SDS. Following transfer, unoccupied sites on membranes were blocked with 10 % sheep serum in PBS containing 0.3 % Tween 20 (PBST) for several hours. Membranes were then probed with horse or rabbit antiserum to purified virus diluted 1 : 200 and 1 : 500 respectively, or rabbit antiserum to EHV-2 and EHV-5 gB fusion protein diluted 1 : i 0 in PBST containing 0.1% BSA and 5 % sheep serum (Western diluent). Membranes were washed in PBST, then soaked in horseradish peroxidase-conjugated goat anti-horse antibody (Kirkegaard and Perry Laboratories) or sheep anti-rabbit antibody (Silenus) diluted 1:400 in Western diluent. Following further washing, membranes were developed using 3,3'-diaminobenzidine and H20 z in 0.1 M-citric acid pH5.
Affinity purification of antibody from selected portions of Western blots. Antibody was affinity purified by elution at low pH, based on the method of Beall & Mitchell (1986) . Briefly, proteins were separated by SDS-PAGE after loading either 30 lag of gB fusion protein or 90 lag of purified virus into a 5 cm well. Following transfer of proteins to PVDF membranes, selected portions of the membranes were excised such that the protein of interest was contained in the cut out portion. Cut membrane strips were blocked to prevent non-specific binding by incubating for 4 h in 10 mg/ml BSA in PBS containing 5 % (v/v) sheep serum. Antiserum to purified virus, or antiserum to gB fusion protein, diluted 1 : 100 or 1 : 10 respectively in Western diluent, was added to the membrane strips overnight with constant rocking. The strips were washed extensively with PBST for 30 min. Antibody was eluted from the membranes by adding 2 ml of 0"1 M-glycine and 0"15 M-NaC1, pH 2"6, for 3 min. The eluate was adjusted to pH 7"5 by addition of 300ml 2M-Tris-HC1 pH7.5, and stored at -70°C. The eluted antibody was diluted 1:2 in Western diluent before use in probing Western blots.
PCR. This technique was used to amplify DNA from the gB genes of EHV-2.86/67 and EHV-5.2-141. A protocol of 35 cycles of 94 °C for 20 s, 54 °C for 20 s and 72 °C for 30 s was followed, using Vent DNA polymerase (New England Biolabs), EHV-2.86/67 or EHV-5.2-141 whole viral DNA as template DNA and the following primers: EHV2.86/67, forward 5' ATGGCACAGAGCCAGAG 3', reverse 5' AGACACTGGCCTGCCAT 3'; EHV5.2-141, forward 5' CAGA-CTATGGTGTGGGG 3', reverse 5' GCTGGCCACGTTCACTA 3'. The primers were designed following analysis of the DNA sequence of random clones of EHV-2 and EHV-5 DNA whose translated products had amino acid sequence similarities to the gB proteins of other gammaherpesviruses (Telford et al., 1993) . The primers were chosen to represent sequences near the left and right extremities of the available gB sequence. A PCR product of 0.71 kb was obtained for EHV-2, predicted to encode about 237 amino acids, which correspond approximately to HVS gB residues 239 to 484. A PCR product of 1'33 kb was obtained for EHV-5, predicted to encode about 443 amino acids, which correspond approximately to HVS gB residues 257 to 682 (Telford et aL, 1993) .
Preparation of EHV-2 and EHV-5 gB recombinant plasmids. EHV-2 gB and EHV-5 gB DNA was ligated into the SrnaI site of the bacterial expression plasmid pGEX-1 (AMRAD) such that the 5' end of the gB gene was adjacent to, and in frame with, the 3" end of the glutathione s-transferase (GST) gene. DNA sequence analysis of the clones was performed to ensure that the DNA inserted into pGEX-1 was EHV-2 and EHV-5 gB DNA. E. coli JM 109 cells (Promega) were transformed with recombinant plasmids using a Gene Pulser Electroporator (Bio- Rad). Small and large scale purification of GST fusion proteins was performed as described previously (Crabb et al., 1992; Crabb & Studdert, 1993) . Costa et al., 1981; Gibson, 1983; Vroman et al., 1985) and it is not glycosylated (see Fig. 2 ). The possible MCP is one of the many protein bands found in common between EHV-5 and EHV-2. However, some notable differences between the profiles of EHV-5 and EHV-2 were apparent. One EHV-2 protein (81 K) and two EHV-5 proteins (105K and 77K) did not have a corresponding protein in the same position for the other virus. It is likely that functional homologues of these proteins are present in the other virus at a different Mr, although it is possible that these proteins are only found in either EHV-2 or EHV-5. As a consequence of the homogeneity of the profiles of the five EHV-2 isolates, our prototype isolate, EHV-2.86/67, was selected to represent EHV-2 in further comparisons with EHV-5.2-141. EHV-2 and EHV-5 glycoproteins were labelled with [x4C]glucosamine and resolved by SDS-PAGE (Fig. 2 ). Significant differences between the M r values of EHV-2 and EHV-5 glycoproteins were apparent. For EHV-2, two strongly labelled glycoproteins of 87K and 72K, and four other glycoproteins of 126K, 107K, 52K and 31K were visible on the gel. EHV-5 has a major glycoprotein of 105K, and five others of 128K, 84K, 77K, 73K and 39K were also identified. Although the glycoproteins of a lower Mr are difficult to discern in Fig. 2 , each glycoprotein was clearly evident on the original autoradiograph. It is possible that the 87K and 72K EHV-2 glycoproteins and the 105K and 77K EHV-5 glycoproteins may be the same proteins that were labelled with [35S]methionine in Fig. 1 , which appear to be specific, at least in size, to either EHV-2 or EHV-5.
Results
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Immunogenicity and cross-reactivity of EHV-2 and EHV-5 antigens
The antigenic relationship between EHV-2 and EHV-5 was examined by ELISA. Wells of microtitre plates were coated with EHV-2 or EHV-5 purified virus, before the addition of serial dilutions of either rabbit antiserum to EHV-2, rabbit antiserum to EHV-5 or horse antiserum to EHV-2. It was found that rabbit antiserum to EHV-5 cross-reacted strongly with EHV-2 (Fig. 3 a) and rabbit antiserum to EHV-2 cross-reacted strongly with EHV-5 (Fig. 3 b) . However, calculation of antibody titres from the curves shows that in both cases the homologous serum had a titre almost 10-fold higher than the heterologous serum. These results indicate that the proteins of EHV-2 and EHV-5 share many common epitopes but also possess type-specific epitopes. The horse antiserum to EHV-2 had a significantly lower titre than the rabbit antiserum to EHV-2. This was probably the result of hyperimmunity in the rabbits following an intensive inoculation schedule with purified virus. However, as with the EHV-2 rabbit antiserum, the EHV-2 horse antiserum bound to EHV-2 significantly better than it did to EHV-5 proteins.
In order to identify the EHV-2 and EHV-5 proteins and glycoproteins that elicit an antibody response, antisera to both viruses were used in RIP analyses of infected cell proteins. EHV-2 (Fig. 4) and EHV-5 (Fig. 5) proteins labelled with [35S]methionine and glycoproteins labelled with [14C]glucosamine were prepared from infected cell extracts and immunoprecipitated with EHV-2 rabbit antiserum, EHV-2 horse antiserum and EHV-5 rabbit antiserum. Included on each gel was a lane of labelled EHV-2-or EHV-5-infected cell extract proteins (nonprecipitated RIP antigen). The antisera were also tested for reactivity with cell proteins from mock-infected E F K cell monolayers. In each RIP performed, a constant amount of antigen and antibody was used. In Fig. 4(a) it can be seen that the rabbit and horse antisera to EHV-2 reacted with approximately 25 and 20 [35S]methioninelabelled EHV-2 proteins respectively. The absence of an antibody reaction to the mock-infected E F K cell preparation suggests that each of the protein bands to which the rabbit and horse antisera bound is an EHV-2 protein and not a cell protein. The possible M C P (about 130K) was strongly immunogenic and another protein of 32K also elicited a particularly strong antibody response. Rabbit antiserum to EHV-5 cross-reacted with approximately 18 EHV-2 proteins. There was a notable lack of binding to EHV-2 proteins of 93K and 37K, suggesting that these proteins may lack homologues in EHV-5, or elicit a type-specific antibody response.
Rabbit and horse antisera to EHV-2 were found to react with three EHV-2 glycoproteins of 126K, 107K and 87K (Fig. 4b ). An EHV-2 glycoprotein of 72K, strongly labelled on the purified virus gel (Fig. 2) , was barely visible in the RIP antigen lane of Fig. 4 (b) , and did not appear to be immunogenic. Rabbit antiserum to EHV-5 cross-reacted with each of the EHV-2 glycoproteins to the same extent as the binding of the homologous sera.
RIP of EHV-5-infected cell extract proteins is shown in Fig. 5(a) . The rabbit antiserum to EHV-5 was reactive with approximately 14 EHV-5 proteins, with the most strongly labelled band being about 106K. A protein of about 130K, the size of the possible MCP, was precipitated by the EHV-5 antiserum, but was not 30K 21.5K I~ Fig. 4 . RIP of (a) [3SS]methionine-and (b) [14C]glucosamine-labelled, detergent solubilized preparations of EHV-2 proteins derived from infected cell extracts by pooled horse and rabbit non-immune serum (Pre), rabbit antiserum to EHV-2 (EHV-2r), horse antiserum to EHV-2 (EHV-2h) and rabbit antiserum to EHV-5 (EHV-5r). Each of the antisera was also used to precipitate proteins prepared from mockinfected EFK cell monolayers (E). A lane of labelled, non-precipitated EHV-2 (2) proteins prepared from infected cell extracts was included. The proteins were separated on 10 % acrytamide gels under reducing conditions. The M r standards used (lane M) are as in Fig. 1 . The rabbit and horse antisera to EHV-2 cross-reacted with about 11 EHV-5 proteins, although binding of the horse EHV-2 antiserum was quite weak. It appears that EHV-5 proteins of 140K, 98K and 48K were not recognized by the EHV-2 sera, and hence may lack a homologue in EHV-2 or otherwise elicit a type-specific antibody response.
EHV-5 glycoproteins (Fig. 5b) of 128K, 105K, 84K, 77K and 73K were recognized by rabbit antiserum to EHV-5. In this case, the rabbit antiserum to EHV-2 bound to a detectable level only with the 105K glycoprotein, whereas the horse antiserum to EHV-2 did not appear to precipitate any EHV-5 glycoproteins. A faint band at 105K was visible in one of the mockinfected antigen lanes of this gel but this is most likely to be the result of spill-over from an adjacent well during loading of the gel, since the high level of binding of EHV-5 antiserum to a protein of this size indicates that it is a viral protein.
EHV-2 and EHV-5 antigens were also examined by Western blot. Purified EHV-2 and EHV-5 virion proteins were separated using SDS-PAGE, transferred to a PVDF membrane and probed with rabbit antiserum to EHV-2, rabbit antiserum to EHV-5 and horse antiserum to EHV-2 (Fig. 6) . The transfer of proteins of high M r from gel to membrane was poor compared with that of proteins of lower M r. A pattern of reactivity similar to that seen in RIP was observed. In the EHV-2 Western blot, the possible MCP (about 130K) and a protein of about 32K were again strongly immunogenic, and antiserum to EHV-5 cross-reacted with most of the EHV-2 proteins, with the notable exception of those of 25K and 24K. One significant difference between the EHV-2 Western blot and the EHV-2 RIP was the strong recognition of a band of about 68K by the horse serum to EHV-2 in the Western blot only. In the EHV-5 Western blot, it could again be seen that the possible MCP was not particularly immunogenic in the rabbit, and that whereas the rabbit antiserum to EHV-2 crossreacted with EHV-5 proteins, binding of the EHV-2 horse antiserum to EHV-5 proteins did not occur to a significant extent, with the exception of proteins of 68K, 36K and 32K. [14C]glucosamine-labelled, detergent solubilized preparations of EHV-5 proteins derived from infected cell extracts by pooled horse and rabbit non-immune serum (Pre), rabbit antiserum to EHV-5 (EHV-5r), rabbit antiserum to EHV-2 (EHV-2r) and horse antiserum to EHV-2 (EHV-2h). Each of the antisera was also used to precipitate proteins prepared from mock-infected EFK cell monolayers (E). A lane of labelled, non-precipitated EHV-5 (5) proteins prepared from infected cell extracts was included. The proteins were separated on 10% acrylamide gels under reducing conditions. The M r standards used (lane M) are as in Fig. 1 . . Western blot analysis of the proteins of EHV-2 and EHV-5 using rabbit antiserum to EHV-2 (2r), rabbit antiserum to EHV-5 (5r), horse antiserum to EHV-2 (2h), non-immune rabbit serum (Pr) and non-immune horse serum (Ph). Approximately 50 lag of purified virus was run on 10 % polyacrylamide gels and the separated proteins were transferred to PVDF membranes. The membranes were cut into strips, one of which was stained with Coomassie Brilliant Blue (C). Other strips were incubated with rabbit serum diluted 1:500 or horse serum diluted 1 : 200. The M r standards used (lane M) are as in Fig. 1 .
Identification of EHV-2 gB
Antiserum to EHV-2 gB fusion protein was raised in a rabbit and used to identify viral EHV-2 gB in Western blots. Purified EHV-2 virion proteins were separated using SDS-PAGE, transferred to a PVDF membrane and probed with antiserum to EHV-2 gB fusion protein and with serum obtained from the same rabbit prior to inoculation (Fig. 7a) . The antiserum to EHV-2 gB bound strongly to an EHV-2 protein of 64K, which was not detected by the pre-immune serum. This protein was therefore considered to comprise EHV-2 gB, or at least one subunit of EHV-2 gB. Although antiserum to EHV-2 gB fusion protein bound strongly to an EHV-2 protein of 64K, the faint recognition of some other bands by this serum necessitated confirmation of the identity of the 64K protein as EHV-2 gB. To this end, affinity purification of antibody to EHV-2 gB fusion protein from a selected portion of a Western blot was performed. EHV-2 gB fusion protein was run on a 10 % acrylamide gel, transferred to a PVDF membrane by Western blot and the region of the membrane between 92"5K and 46K was excised. This strip of membrane was incubated overnight with rabbit antiserum to EHV-2 gB fusion protein. Antibody eluted from this strip was then used to probe EHV-2 purified virus (Fig. 7b) . It was found that the eluted antibody bound only to a band of 64K. The adjacent lane in Fig.  7(b) shows that the 64K band is an immunodominant protein recognized by horse antiserum to EHV-2 purified In a separate experiment, EHV-2 and EHV-5 purified virus was probed with 2efp antibody, and EHV-5 purified virus was probed with rabbit antiserum to EHV-5 purified virus (5p).
virus. In a separate experiment, binding of the eluted antibody to EHV-2 gB fusion protein to EHV-5 purified virus was investigated (Fig. 7c) . EHV-2 and EHV-5 purified virus run on the same gel were both probed with the eluted antibody to EHV-2 gB fusion protein, but the eluted antibody only bound to the 64K EHV-2 protein.
Binding of rabbit antiserum to EHV-5 purified virus to EHV-5 proteins in an adjacent lane was a control for the presence of sufficient EHV-5 in the EHV-5 lanes. Therefore, it appears that the antiserum raised in a rabbit to EHV-2 gB fusion protein was specific for EHV-2 gB.
Identification of EHV-5 gB
Antiserum to EHV-5 gB fusion protein was raised in a rabbit and used in Western blots in an attempt to identify EHV-5 gB. When tested for its ability to bind to EHV-5 purified virus, the antiserum to EHV-5 gB fusion protein bound weakly to several proteins, which were also recognized by pre-immune serum (data not shown) and therefore it was not possible to establish which protein was EHV-5 gB using the antiserum to the EHV-5 gB fusion protein.
As a result, an alternative approach using affinitypurified antibody to EHV-2 and EHV-5 purified virus proteins was used to identify EHV-5 gB. For EHV-2, horse antibody to the 64K gB band was affinity-purified, while for EHV-5, rabbit antibody to proteins of 66K and 48K was purified. The 66K EHV-5 protein was chosen as a candidate for EHV-5 gB on the basis of its similarity in size to the 64K EHV-2 gB species, while the 48K protein was chosen on the basis of recognition of this band, which was presumably non-specific, by the rabbit antiserum to EHV-5 gB fusion protein (data not shown). The EHV-2 gB-eluted antibody was used to probe EHV-5 purified virus alongside rabbit antiserum to EHV-5 purified virus (Fig. 8a) . The EHV-2 gB antibody recognized an immunodominant EHV-5 protein of 66K, which was thus identified as EHV-5 gB. This was confirmed in a reciprocal experiment using eluted antibody to the two EHV-5 proteins to probe EHV-2 purified virus alongside horse antiserum to EHV-2 purified virus (Fig. 8b) . EHV-5 antibody to the 66K protein bound to EHV-2 gB, whereas EHV-5 antibody to the 48K protein did not bind to EHV-2 gB.
Discussion
In this study, the protein and glycoprotein profiles of EHV-2 and EHV-5 were compared. Five different EHV-2 isolates were chosen for analysis on the basis of the heterogeneity of their genomic restriction endonuclease fingerprints (Browning & Studdert, 1989b) . The [35S]-methionine-labelled protein profiles of the five EHV-2 were very similar, with conservation of all major proteins and only small shifts in the M r of a couple of minor bands, showing that in spite of the genomic differences (Browning & Studdert, 1987 , 1989b and antigenic heterogeneity (Plummer et al., 1973) , the five EHV-2 isolates have almost identical structural proteins. Corn-parison of the EHV-2 and EHV-5 protein and glycoprotein profiles revealed some major differences. For EHV-2, six glycoproteins of 126K, 107K, 87K, 72K, 52K and 31K were identified and for EHV-5, six glycoproteins of 128K, 105K, 84K, 77K, 73K and 39K were identified. The number of glycoproteins and the span of the M r values suggest that a homologue of approximately similar size exists for each virus. However, the [l*C]glucosaminelabelled glycoprotein profiles (Fig. 2) showed significant variation in the location of the intensely labelled glycoproteins. Possible explanations for differences between the EHV-2 and EHV-5 glycoprotein profiles are either that EHV-2 and EHV-5 have functionally homologous glycoproteins of a similar size but of different abundance, which resulted in the differences in the intensity of labelling or that functional homologues of EHV-2 and EHV-5 glycoproteins of similar abundance have different M r values. A further possibility is that each virus possesses glycoproteins that are not shared by the other.
The proteins and glycoproteins of EHV-2. LK were studied previously by Caughman et al. (1984) , who found that EHV-2 nucleocapsids are composed of nine proteins (average M r values of 148K, 52K, 49"5K, 46K, 43.5K, 38.5K, 27K, 20K and 18K) , and identified the 148K protein as the MCP. Enveloped virions were found to be composed of at least 37 proteins ranging in M r from over 200K to 14K. At least 14 of these proteins were detected in infected cell lysates and 11 of these were immunoprecipitated by rabbit antiserum raised against purified virus. A major glycoprotein band was found to migrate at an Mr of approximately 71K and to consist of a non-glycosylated 71K protein and three glycosylated bands of 83K, 78K and 73.5K. Four glycoproteins of lower abundance (111K, 68K, 61K and 41K) were also detected and long ftuorographic exposure of gels revealed four further bands (20K, 152K, 43-5K and 18K). These results indicate that there is little difference between the proteins ofEHV-2. LK and EHV-2.86/67. The M r values assigned to particular proteins such as the MCP showed some variation, but these discrepancies can be attributed to variations in electrophoretic conditions, and in the reading of the M r values from the standards. For the EHV-2 glycoproteins, a visual comparison of the EHV-2. LK and EHV-2.86/67 profiles suggests that the 111K, 71K and 61K proteins described by Caughman et aL (1984) are equivalent to the 107K, 87K and 72K proteins described here. Like the 71K protein of EHV-2. LK, it is possible that the 87K EHV-2.86/67 glycoprotein band also consists of two or more individual glycoproteins.
Re-interpretation of cross-neutralization data on 10 slow-growing EHV isolates (Plummer et al., 1973) revealed that there are significant antigenic differences between EHV-5 and EHV-2. Antiserum raised in rabbits against EHV-5.2-141 cross-reacted to a significant extent with EHV-5.3-141 but not with seven EHV-2 strains. In these studies, the immunogenicity and cross-reactivity of EHV-2 and EHV-5 proteins and glycoproteins were examined using ELISA, RIP and Western blot. The results indicated that EHV-2 and EHV-5 possess both type-common and type-specific epitopes. Two points can be noted from the RIP and the Western blot data. Firstly, the possible EHV-5 MCP, identified as 130K in Fig. 1 , did not appear to be highly immunogenic. This was in marked contrast to the possible MCP of EHV-2, as shown here and also by Caughman et al. (1984) . Secondly, the horse antiserum to EHV-2 bound to EHV-5 proteins to a much lesser extent than the rabbit antiserum to EHV-2. This may be indicative of the differences in the immune responses of a natural host infected with live virus, and of a non-natural host inoculated with virus in adjuvant. The use of antisera raised in single animals in these studies has its limitations. It is possible that in different animals the immunodominant virion proteins may vary.
EHV-2 and EHV-5 have amino acid sequence homology with the gB homologues of EBV and HVS (Telford et al., 1993) . The EBV gB homologue (Pellett et al., 1985) , designated gp110 (and 110K in size), is one of the most abundant EBV proteins. However, unlike herpes simplex virus gB, which is an abundant virion and infected cell-surface glycoprotein, gp110 is not a major structural protein of the EBV virion (Gong et al., 1987; Gong & Kieff, 1990) . In the present study, EHV-2 gB and EHV-5 gB species were identified in purified virions as proteins of 64K and 66K respectively. Herpesvirus gB homologues commonly occur as disulphide-linked heterodimers. Rabbit antiserum to EHV-2 gB fusion protein bound only to a 64K EHV-2 protein suggesting that if EHV-2 gB is a heterodimer, only epitopes in the region of the EHV-2 gB gene encoding the 64K subunit were expressed.
Attempts to identify EHV-5 gB using the antiserum raised in a rabbit to EHV-5 gB fusion protein were unsuccessful. While DNA sequencing of the EHV-5 gB pGEX-1 clone indicated that the sequence of the viral DNA constituting the clone was identical to the sequence described by Telford et al. (1993) for EHV-5 gB, the sequencing primer used was directed to a region close to the cloning site, which, as a result, could not be sequenced in this or any other of our pGEX plasmids (data not shown). Therefore, a possible explanation for the failure of the rabbit to produce EHV-5 gB-specific antibody is that EHV-5 gB DNA was inserted into pGEX-1 in the wrong reading frame.
It was apparent from Fig. 8 that the identified EHV-2 and EHV-5 gB species were cross-reactive, as antibody affinity-purified to either EHV-2 or EHV-5 gB reacted with the heterologous gB species. However, the epitopes expressed by the EHV-2 gB fusion protein were typespecific. With identification of an immunodominant EHV-2 gB species of 64K and an immunodominant EHV-5 gB species of 66K (Fig. 7 and 8) , the [aSS]methionine and [14C]glucosamine EHV-2 and EHV-5 profile gels, the RIPs and the Western blot shown in Fig. 6 were examined retrospectively in an attempt to locate the gB species. In the [35S]methionine-labelled protein profiles of EHV-2 and EHV-5, bands at about 69K are most probably EHV-2 and EHV-5 gB. In the [35S]methioninelabelled EHV-5 RIP, a protein just below 69K was immunodominant and cross-reactive with EHV-2 antisera. In the [35S]methionine-labelled EHV-2 RIP, however, the immunogenicity of gB was more difficult to discern. Several bands around 69K were precipitated and none of them was particularly immunogenic. In the EHV-2 and EH¥-5 Western blots, proteins of about 68K were strongly immunodominant, particularly in the horse. It is possible that the linear epitopes occurring in Western blots were more readily recognized by gB antibody than were the conformational epitopes occurring in RIP, or that gB does not solubilize well in RIP (although this is considered unlikely). It is clear, however, from the Western blot analysis of EHV-2 and EHV-5 proteins, that the 64K and 66K gB species identified in this study are strongly immunodominant.
In the [14C]glucosamine-labelled glycoprotein profiles of EHV-2 and EHV-5, there were no labelled glycoproteins visible at 64K or 66K respectively. A possible explanation for this is that the 64K and 66K species of EHV-2 and EHV-5 gB are poorly glycosylated. The absence of [14C]glucosamine-labelled bands at 64K and 66K suggests that a further, as yet unidentified, glycosylated subunit(s) of EHV-2 and EHV-5 gB might exist.
